首页> 外文OA文献 >Transcriptomic signature predicts the distant relapse in patients with ER+ breast cancer treated with tamoxifen for five years

【2h】

Transcriptomic signature predicts the distant relapse in patients with ER+ breast cancer treated with tamoxifen for five years

机译：转录组签名预测，用他莫昔芬治疗的ER +乳腺癌患者的遥远复发五年

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Hao Zhou; Qingfu Lv; Zhaoji Guo;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Transcriptomic signature predicts the distant relapse in patients with ER plus breast cancer treated with tamoxifen for five years [J] . Zhou Hao, Lv Qingfu, Guo Zhaoji Molecular medicine reports . 2018,第2aPta2期

机译：转录组签名预测患者患者患者的遥远复发，用他莫昔芬治疗五年治疗
2. Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting [J] . Anieta M. Sieuwerts, Maria B. Lyng, Marion E. Meijer-van Gelder, Molecular oncology. . 2014,第8期

机译：评估他莫昔芬-获益基因信号辅助剂在晚期环境中接受他莫昔芬治疗时未接受激素的雌激素受体阳性乳腺癌患者的结局预测能力
3. A Five-Gene Model Predicts Clinical Outcome in ER+/PR+, Early-Stage Breast Cancers Treated with Adjuvant Tamoxifen [J] . Hormones & cancer . 2011,第5期

机译：五基因模型预测用他莫昔芬辅助治疗的ER + / PR +早期乳腺癌的临床结果
4. Proteomic Signatures of Tamoxifen Resistance in Breast Cancer [C] . Changhua Zhou, Lindsay Rhodes, Ian Townley, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：乳腺癌中三种毒性抗性的蛋白质组学特征
5. Translational Reprogramming by eIF4E in Tamoxifen-Resistant ER+ Breast Cancer. [D] . Geter, Phillip A. 2018

机译：eIF4E在抗他莫昔芬的ER +乳腺癌中进行翻译重编程。
6. The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures [O] . Jessica G. Cockburn, Robin M. Hallett, Amy E. Gillgrass, 2016

机译：淋巴结状况对ER + / HER2-他莫昔芬治疗的乳腺癌患者基因表达预测结果的影响
7. The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures [O] . Jessica G. Cockburn, Robin M. Hallett, Amy E. Gillgrass, 2016

机译：淋巴结状况对ER + / HER2-他莫昔芬治疗的乳腺癌患者基因表达预测结果的影响
8. Pin1 as a Biomarker of ER+ Breast Cancers to Predict the Response to Tamoxifen and mTOR Inhibitors [R] . Barberi, T. 2010

机译：pin1作为ER +乳腺癌的生物标志物预测对他莫昔芬和mTOR抑制剂的反应

Transcriptomic signature predicts the distant relapse in patients with ER+ breast cancer treated with tamoxifen for five years

著录项

引文网络

相似文献

相关主题

期刊订阅